New data from Zafgen's Prader-Willi study

Zafgen Inc. (NASDAQ:ZFGN) presented secondary endpoint data from the Phase III bestPWS (ZAF-311) trial evaluating subcutaneous beloranib ( ZGN-440) to treat Prader-Willi syndrome. Data were presented at the

Read the full 282 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE